In silico screening of phytopolyphenolics for the identification of bioactive compounds as novel protease inhibitors effective against SARS-CoV-2

Abstract

Due to the unavailability specific drugs or vaccines (FDA approved) that can cure COVID-19, the development of potent antiviral drug candidates/therapeutic molecules against COVID-19 is urgently required. This study was aimed at in silico screening and study of polyphenolic phytochemical compounds in a rational way by virtual screening, molecular docking and molecular dynamics studies against SARS-CoV-2 main protease (Mpro) and papain-like protease (PLpro) enzymes. The objective of the study was to identify plant-derived polyphenolic compounds and/or flavonoid molecules as possible antiviral agents with protease inhibitory potential against SARS-CoV-2. In this study, we report plant-derived polyphenolic compounds (including flavonoids) as novel protease inhibitors against SARS-CoV-2. From virtual docking and molecular docking study, 31 polyphenolic compounds were identified as active antiviral molecules possessing well-defined binding affinity with acceptable ADMET, toxicity and lead-like or drug-like properties. Six polyphenolic compounds, namely, enterodiol, taxifolin, eriodictyol, leucopelargonidin, morin and myricetin were found to exhibit remarkable binding affinities against the proteases with taxifolin and morin exhibiting the highest binding affinity toward Mpro and PLpro respectively. Molecular dynamics simulation studies of these compounds in complex with the proteases showed that the binding of the compounds is characterized by structural perturbations of the proteases suggesting their antiviral activities. These compounds can therefore be investigated further by in vivo and in vitro techniques to assess their potential efficacy against SARS-CoV-2 and thus serve as the starting point for the development of potent antiviral agents against the deadly COVID-19.

Communicated by Ramaswamy H. Sarma

Keywords:

• SARS-CoV-2
• phytomedicine
• polyphenolics
• flavonoids
• protease inhibitors
• molecular docking
• MD simulation

Disclosure statement

Authors declare that there is no potential conflict of interest.

Authors’ contribution

M. Rudrapal: Conceptualization, Methodology, Original Draft Preparation, Reviewing, Editing and Final Proof Reading; A. R. Issahaku: Methodology, Analysis and Final Draft Preparation; C. Agoni: Methodology and Data curation; A. R. Bendale: Visualization, Investigation; A. Nagar: Analysis and Validation; M. E. S. Soliman: Methodology and Analysis; D. Lokwani: Software and Validation.